Baird Reiterates Outperform on Ocular Therapeutix, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy has reiterated an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a price target of $18.
September 14, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst has reiterated an Outperform rating on Ocular Therapeutix and maintained a price target of $18.
The reiteration of an Outperform rating by Baird analyst Colleen Kusy indicates a positive outlook for Ocular Therapeutix. The maintained price target of $18 also suggests that the analyst believes the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100